BIIB Stock Report - Biogen Idec Inc.
Biogen Inc. is a biotechnology company that focuses on discovering, developing, manufacturing,
and delivering therapies for treating neurological and neurodegenerative diseases. The company
offers several treatments for multiple sclerosis, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY,
TYSABRI, and FAMPYRA. Biogen also provides SPINRAZA for spinal muscular atrophy, FUMADERM to
treat plaque psoriasis, and biosimilars referencing ENBREL, HUMIRA, and REMICADE for various
conditions.
The company has a strong pipeline of products under development, including treatments for MS and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropathic pain, and immunology related diseases. Biogen has collaboration and license agreements with various companies, including Acorda Therapeutics, Eisai Co., Ltd., and Sage Therapeutics, among others. Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts. The company is committed to developing innovative therapies to improve the lives of patients suffering from neurological and neurodegenerative d
|
||||||||||||
|
|
||||||||||||
|
||||||||||||
|
|
Privacy Policy | Refund Policy | Disclaimer